不治不付酬。
No cure, no pay.
作者信息
Møldrup Claus
机构信息
Department of Social Pharmacy, Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark.
出版信息
BMJ. 2005 May 28;330(7502):1262-4. doi: 10.1136/bmj.330.7502.1262.
Abstract
Not paying for a drug unless it works sounds great for patients and healthcare funders, but it could also benefit manufacturers.
摘要
除非药物有效否则就不付费，这对患者和医疗保健资助者来说听起来很棒，但这也可能使制药商受益。
相似文献
1
No cure, no pay.不治不付酬。
BMJ. 2005 May 28;330(7502):1262-4. doi: 10.1136/bmj.330.7502.1262.
2
Pharmaceutical expenditure compared across countries.各国药品支出对比。
Can J Clin Pharmacol. 2005 Fall;12(3):e269-75. Epub 2005 Dec 1.
3
[Medicoeconomic data on rare disease drugs: a move towards more transparency?].[罕见病药物的药物经济学数据：朝着更高透明度迈进？]
Presse Med. 2012 May;41 Suppl 1:S57-64. doi: 10.1016/j.lpm.2012.02.024. Epub 2012 Apr 8.
4
[Drug shortage--cause and prevention].[药品短缺——原因与预防]
Tidsskr Nor Laegeforen. 2012 Oct 16;132(19):2154-5. doi: 10.4045/tidsskr.12.0668.
5
Vendor competition, generic drugs spur drop in pharmaceutical prices.供应商竞争、仿制药促使药品价格下降。
Mod Healthc. 1985 Oct 11;15(21):56, 60-2.
6
European prices of newly launched reimbursable pharmaceuticals--a pilot study.新上市可报销药品的欧洲价格——一项试点研究。
Health Policy. 2005 Nov;74(3):235-46. doi: 10.1016/j.healthpol.2005.01.005.
7
Prescription drug pricing: the consumer perspective.处方药定价：消费者视角
N C Med J. 2003 Nov-Dec;64(6):300-2.
8
New rules for US drug reimbursement.美国药品报销新规。
Nat Biotechnol. 2003 Oct;21(10):1119-20. doi: 10.1038/nbt878.
9
Face-off will new drugs pay off in time to counter patent losses for Forest Laboratories?新药能否及时取得成效以应对福瑞斯特实验室的专利损失？
Fortune. 2012 Jun 11;165(8):80.
10
[Proposal on reviewing the overall healthcare expenditure and its allocation: focusing on medication expenses].关于审查整体医疗保健支出及其分配的提议：聚焦于药物费用
Nihon Geka Gakkai Zasshi. 2010 May;111(3):189-94.
引用本文的文献
1
Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.新型药物与绩效挂钩的报销激励的利弊：沙库巴曲缬沙坦的案例。
Circ Cardiovasc Qual Outcomes. 2022 Jan;15(1):e007993. doi: 10.1161/CIRCOUTCOMES.121.007993. Epub 2022 Jan 18.
2
Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.美国药品的基于绩效的风险分担安排：系统评价。
J Manag Care Spec Pharm. 2017 Oct;23(10):1028-1040. doi: 10.18553/jmcp.2017.23.10.1028.
3
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.药品风险分担安排：对欧洲支付方的潜在考虑和建议。
BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.
4
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.为无法资助的项目提供资金：在将新技术和创新技术引入医疗保健系统的决策中管理不确定性的机制。
Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000.
5
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.无法获得满足感？付费绩效能否有所帮助？：理解创新型医疗产品基于绩效的风险分担协议的经济框架。
Pharmacoeconomics. 2010;28(2):93-102. doi: 10.2165/11314080-000000000-00000.
6
What do patients want from their psychiatrist? A cross- sectional questionnaire based exploratory study from Karachi.患者对精神科医生有何期望？一项来自卡拉奇的基于横断面问卷调查的探索性研究。
BMC Psychiatry. 2008 Feb 29;8:14. doi: 10.1186/1471-244X-8-14.
7
Rationing of drugs for rare diseases.罕见病药物的配给
Pharmacoeconomics. 2006;24(4):315-6. doi: 10.2165/00019053-200624040-00001.
本文引用的文献
1
Medicine as a business.作为商业的医学。
Mt Sinai J Med. 2004 Sep;71(4):225-30.
2
"Me-too" products--friend or foe?“Me-too”产品——是友还是敌？
N Engl J Med. 2004 Jan 15;350(3):211-2. doi: 10.1056/NEJMp038215.
3
Healthcare reform through rationing.通过配给进行医疗保健改革。
J Healthc Manag. 2003 Jul-Aug;48(4):233-41.
4
Ethical, social and legal implications of pharmacogenomics: a critical review.药物基因组学的伦理、社会及法律影响：批判性综述
Community Genet. 2001;4(4):204-14. doi: 10.1159/000064194.
5
The health cost of doing business.营商的健康成本。
Health Matrix. 1985 Fall;3(3):32-6.
6
Academic medicine must deal with the clash of business and professional values.学术医学必须应对商业价值与专业价值之间的冲突。
Acad Med. 1998 Jul;73(7):751-5. doi: 10.1097/00001888-199807000-00010.
7
Merck offers money back guarantee on finasteride.默克公司提供非那雄胺退款保证。
BMJ. 1994 Nov 12;309(6964):1252-3. doi: 10.1136/bmj.309.6964.1252a.
8
Success rates for new drugs entering clinical testing in the United States.进入美国临床测试的新药成功率。
Clin Pharmacol Ther. 1995 Jul;58(1):1-14. doi: 10.1016/0009-9236(95)90066-7.
Zotero 插件